After this initial discovery, numerous studies have contributed evidence supporting the role of mutant p53 as a tumor antigen and the therapeutic potential of targeting mutant p53 with adoptive cell therapies (McCarty et al., 1998). The gene discussed is TP53; the disease is neoplasm.